LeMaitre Vascular (NASDAQ:LMAT) & Anteris Technologies Global (NASDAQ:AVR) Head to Head Comparison

LeMaitre Vascular (NASDAQ:LMAT) and Anteris Technologies Global (NASDAQ:AVR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares LeMaitre Vascular and Anteris Technologies Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	23.51%	15.33%	9.97%
Anteris Technologies Global	-4,637.48%	-61.24%	-54.97%

Insider & Institutional Ownership

84.6% of LeMaitre Vascular shares are owned by institutional investors. 7.4% of LeMaitre Vascular shares are owned by insiders. Comparatively, 4.5% of Anteris Technologies Global shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for LeMaitre Vascular and Anteris Technologies Global, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0	5	3	0	2.38
Anteris Technologies Global	1	1	3	0	2.40

LeMaitre Vascular currently has a consensus price target of $108.25, indicating a potential upside of 36.52%. Anteris Technologies Global has a consensus price target of $14.00, indicating a potential upside of 125.81%. Given Anteris Technologies Global’s stronger consensus rating and higher probable upside, analysts plainly believe Anteris Technologies Global is more favorable than LeMaitre Vascular.

Volatility & Risk

LeMaitre Vascular has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Anteris Technologies Global has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500.

Earnings and Valuation

This table compares LeMaitre Vascular and Anteris Technologies Global”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60 million	7.27	$57.73 million	$2.75	28.83
Anteris Technologies Global	$1.91 million	316.46	-$94.14 million	($1.95)	-3.18

LeMaitre Vascular has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Summary

LeMaitre Vascular beats Anteris Technologies Global on 9 of the 13 factors compared between the two stocks.

About LeMaitre Vascular

LeMaitre Vascular develops, manufactures and markets medical devices used primarily in the treatment of vascular disease. Its products support procedures performed by vascular surgeons and include vascular grafts, embolectomy catheters, carotid shunts, valvulotomes and other instruments used in vascular surgery. Founded in 1983 by vascular surgeon George LeMaitre, the company is headquartered in Burlington, Massachusetts. Its products are sold to hospitals and medical professionals around the world through a combination of direct sales and distributors.

About Anteris Technologies Global

Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.